ImmunoMetabolix

About

Is a clinical-stage biotechnology company focused on applying a novel engineering approach to develop metabolically-fit immunotherapies for patients with cancer, autoimmune, and inflammatory diseases.

Product

Value proposition

A novel approach for patients with cancer, autoimmune, and inflammatory diseases through metabolically-fit immune cells (IMET platform) to treat cancer and inflammatory conditions.

Founders

• Abhinav Acharya — Founder & Chief Scientific Officer
• Vladimir A. Castillo — Chief Executive Officer

Categories

Products

Key features

Technologies

Target conditions

Care settings

News

• ImmunoMet Therapeutics Presents Updated Clinical Data from Phase 1b Study of Lixumistat in Pancreatic Cancer at ASCO-GI Meeting · 2025-01-24T00:00:00.000Z
• Immunomet Therapeutics has filed a notice of an exempt offering of securities to raise $10 Million in New Funding. - intelligence360 · 2026-03-05T15:15:00.000Z
• ImmunoMet's Lixumistat Achieves 100% Disease Control in Pancreatic Cancer Trial · 2025-05-26T00:00:00.000Z
• ImmunoMet Therapeutics Presents Updated Clinical Data from Phase 1b Study of Lixumistat in Pancreatic Cancer at ASCO-GI Meeting - 뉴스와이어 · 2025-01-30T02:55:00.000Z
• Breaking New Ground: iMetabolic Biopharma Corporation's iPlatformTM Revolutionizes Advanced Drug R&D · 2024-08-08T01:22:55.000Z
• The Blogs: Restoring Metabolic Balance to Fight Cancer | Dror Bin | The Times of Israel

Browse related software

• Clinic software in NJ
• Clinic software in Bridgewater
• BioTech software
• Healthcare Startup software
• All clinic software companies A–Z

More links